A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies

• Status: Completed
• Trial end date: 2016-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is to determine the appropriate dosing regimen of GS-9820 in subjects with lymphoid malignancies. This is a Phase 1b, open-label, dose-escalation and expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of GS-9820.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gilead Sciences

Criteria

Inclusion Criteria:

• Previously treated recurrent B-cell iNHL, DLBCL, MCL, HL or CLL

• Measurable lymphadenopathy

• Requires therapy

Exclusion Criteria:

• Recent history of a major non-lymphoid malignancy

• Evidence of ongoing infection

• Concurrent participation in another therapeutic clinical trial